WO2007037788A1 - Composition d'anticorps et immunisation passive contre l’hypertension induite par une grossesse au moyen d'anticorps antidigoxine (digibind) - Google Patents

Composition d'anticorps et immunisation passive contre l’hypertension induite par une grossesse au moyen d'anticorps antidigoxine (digibind) Download PDF

Info

Publication number
WO2007037788A1
WO2007037788A1 PCT/US2006/018876 US2006018876W WO2007037788A1 WO 2007037788 A1 WO2007037788 A1 WO 2007037788A1 US 2006018876 W US2006018876 W US 2006018876W WO 2007037788 A1 WO2007037788 A1 WO 2007037788A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
digoxin
antibody
mammal
therapeutically effective
Prior art date
Application number
PCT/US2006/018876
Other languages
English (en)
Inventor
Charles David Adair
Original Assignee
Charles David Adair
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles David Adair filed Critical Charles David Adair
Publication of WO2007037788A1 publication Critical patent/WO2007037788A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention concerne une composition pour empêcher, limiter les effets de, différer le début de ou traiter une ou plusieurs causes, symptômes ou complications d'une hypertension de gestation, d’une prééclampsie, d'une éclampsie et/ou d’une restriction de croissance intra-utérine. La composition comprend, comme principe actif, une quantité thérapeutiquement efficace d'un anticorps qui réagit immunologiquement avec ou se lie à la digoxine et possède une capacité de liaison à une haute dose de digoxine. Elle concerne aussi une méthode pour empêcher, limiter les effets de, différer le début de, ou traiter une cause, un symptôme ou une complication d'hypertension de gestation, de prééclampsie, d'éclampsie et/ou de restriction de croissance intra-utérine, qui consiste en une étape d'administration à un mammifère d’une composition contenant une quantité thérapeutiquement efficace d'un anticorps qui réagit immunologiquement avec ou se lie à la digoxine et possède une capacité de liaison à une haute dose de digoxine.
PCT/US2006/018876 2005-05-17 2006-05-16 Composition d'anticorps et immunisation passive contre l’hypertension induite par une grossesse au moyen d'anticorps antidigoxine (digibind) WO2007037788A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68169305P 2005-05-17 2005-05-17
US60/681,693 2005-05-17

Publications (1)

Publication Number Publication Date
WO2007037788A1 true WO2007037788A1 (fr) 2007-04-05

Family

ID=37024742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018876 WO2007037788A1 (fr) 2005-05-17 2006-05-16 Composition d'anticorps et immunisation passive contre l’hypertension induite par une grossesse au moyen d'anticorps antidigoxine (digibind)

Country Status (1)

Country Link
WO (1) WO2007037788A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515534A (ja) * 2013-03-15 2016-05-30 ヴェロ バイオ，エルエルシー 子癇症及び子癇前症を治療するための方法
CN116396392A (zh) * 2023-01-17 2023-07-07 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011028A1 (fr) * 2002-07-25 2004-02-05 Charles David Adair Utilisation d'un fragment fab immune de digoxine dans la regulation de l'activite atpase sodium/potassium chez des patients preeclamptiques et eclamptiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011028A1 (fr) * 2002-07-25 2004-02-05 Charles David Adair Utilisation d'un fragment fab immune de digoxine dans la regulation de l'activite atpase sodium/potassium chez des patients preeclamptiques et eclamptiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADAIR C D ET AL: "Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin.", AMERICAN JOURNAL OF NEPHROLOGY. SWITZERLAND 1996, vol. 16, no. 6, 1996, pages 529 - 531, XP008025479, ISSN: 0250-8095 *
BAILEY BENOIT: "Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women?", BIRTH DEFECTS RESEARCH, vol. 67, no. 2, February 2003 (2003-02-01), pages 133 - 140, XP008025290, ISSN: 1542-0752 (ISSN print) *
GOODLIN R C: "Antidigoxin antibodies in eclampsia.", THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 25 FEB 1988, vol. 318, no. 8, 25 February 1988 (1988-02-25), pages 518 - 519, XP008025492, ISSN: 0028-4793 *
GOTO A ET AL: "Ouabain-like factor.", CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION. UNITED STATES MAR 1998, vol. 7, no. 2, March 1998 (1998-03-01), pages 189 - 196, XP000917769, ISSN: 1062-4821 *
LOPATIN D A ET AL: "Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia", JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 17, no. 8, August 1999 (1999-08-01), pages 1179 - 1187, XP008025481, ISSN: 0263-6352 *
PULLEN MARK A ET AL: "Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. JUL 2004, vol. 310, no. 1, July 2004 (2004-07-01), pages 319 - 325, XP002401279, ISSN: 0022-3565 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515534A (ja) * 2013-03-15 2016-05-30 ヴェロ バイオ，エルエルシー 子癇症及び子癇前症を治療するための方法
EP2968986A4 (fr) * 2013-03-15 2017-01-18 Velo Bio, LLC Procédé permettant de traiter l'éclampsie et la prééclampsie
EP3449977A1 (fr) * 2013-03-15 2019-03-06 Velo Bio, LLC Procédé de traitement de l'éclampsie et de la prééclampsie
CN116396392A (zh) * 2023-01-17 2023-07-07 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用

Similar Documents

Publication Publication Date Title
US8119134B2 (en) Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia
Houwing et al. Sickle cell disease: clinical presentation and management of a global health challenge
JP7003354B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
CN111511390A (zh) 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
US11439682B2 (en) Treating IgE-mediated allergic diseases
Haller et al. Type 1 diabetes in the child and adolescent
WO2007037788A1 (fr) Composition d'anticorps et immunisation passive contre l’hypertension induite par une grossesse au moyen d'anticorps antidigoxine (digibind)
JP2018515442A (ja) 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体
US20220380451A1 (en) Biopharmaceutical compositions and methods for pediatric patients
US20210139573A1 (en) Dosing regimens for treating or preventing c5-associated diseases
EP1519746B1 (fr) Utilisation d'un fragment fab immune de digoxine dans la regulation de l'activite atpase sodium/potassium chez des patients preeclamptiques et eclamptiques
US7402313B2 (en) Method for controlling preeclampsia and eclampsia
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
US20200172603A1 (en) Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
US20200055942A1 (en) Treatment regimens
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
WO2021220216A1 (fr) Méthodes pour éliminer une hémorragie vitreuse
CN113260628A (zh) 治疗支气管肺发育不良的抗flt-1抗体
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06759911

Country of ref document: EP

Kind code of ref document: A1